Jim Cramer's Mad Dash: Good News for Regeneron

NEW YORK (TheStreet) -- Shares of Regeneron (REGN) are up almost 10% in Wednesday's trading session, and the stock was the focus on CNBC's "Cramer's Mad Dash" segment.   

The company is having a "breakthrough" with its cholesterol drug. Its other drug, Eylea, was just approved by the Food and Drug Administration following positive Phase III results, according to TheStreet's Jim Cramer, co-manager of the Action Alerts PLUS portfolio

It's cholesterol treatment is the world's first alternative to statin drugs, which many people are allergic too, he said. 

Read More: How Twitter's Blowout Quarter Changed My Mind

Biotechnology stocks continue to move higher, while large-cap pharmaceutical stocks remain stagnant amid slower growth. 

Gilead Sciences (GILD) is the "cheapest drug company I follow," Cramer concluded, before adding that Regeneron's cholesterol drug could become a household product in the future.

-- Written by Bret Kenwell in Petoskey, Mich.

Read More: Alaska Air's Secret Weapon Against Delta

At the time of publication, Cramer's Action Alerts PLUS had no position in companies mentioned.

If you liked this article you might like

Regeneron Pharmaceuticals Ready to Make All-Time Highs

Regeneron, BioMarin, AbbVie Could Explode 20% or More -- Analyst

Biotech movers: CEL-SCI Leaps After FDA Lets Cancer Study Move Forward

If It's Not Earnings News, It's Amazon Competition: Jim Cramer's Best Blog

Electronic Arts, Activision Blizzard and Take-Two Interactive: 'Mad Money' Lightning Round